Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Neuropharmacology
2012 Mar 01;624:1730-6. doi: 10.1016/j.neuropharm.2011.11.019.
Show Gene links
Show Anatomy links
Structure-activity relationships for allosteric NMDA receptor inhibitors based on 2-naphthoic acid.
Costa BM
,
Irvine MW
,
Fang G
,
Eaves RJ
,
Mayo-Martin MB
,
Laube B
,
Jane DE
,
Monaghan DT
.
???displayArticle.abstract???
Over-activation of N-methyl-d-aspartate (NMDA) receptors is critically involved in many neurological conditions, thus there has been considerable interest in developing NMDA receptor antagonists. We have recently identified a series of naphthoic and phenanthroic acid compounds that allosterically modulate NMDA receptors through a novel mechanism of action. In the present study, we have determined the structure-activity relationships of 18 naphthoic acid derivatives for the ability to inhibit the four GluN1/GluN2(A-D) NMDA receptor subtypes. 2-Naphthoic acid has low activity at GluN2A-containing receptors and yet lower activity at other NMDA receptors. 3-Amino addition, and especially 3-hydroxy addition, to 2-naphthoic acid increased inhibitory activity at GluN1/GluN2C and GluN1/GluN2D receptors. Further halogen and phenyl substitutions to 2-hydroxy-3-naphthoic acid leads to several relatively potent inhibitors, the most potent of which is UBP618 (1-bromo-2-hydroxy-6-phenylnaphthalene-3-carboxylic acid) with an IC(50) ∼ 2 μM at each of the NMDA receptor subtypes. While UBP618 is non-selective, elimination of the hydroxyl group in UBP618, as in UBP628 and UBP608, leads to an increase in GluN1/GluN2A selectivity. Of the compounds evaluated, specifically those with a 6-phenyl substitution were less able to fully inhibit GluN1/GluN2A, GluN1/GluN2B and GluN1/GluN2C responses (maximal % inhibition of 60-90%). Such antagonists may potentially have reduced adverse effects by not excessively blocking NMDA receptor signaling. Together, these studies reveal discrete structure-activity relationships for the allosteric antagonism of NMDA receptors that may facilitate the development of NMDA receptor modulator agents for a variety of neuropsychiatric and neurological conditions.
Balannik,
Molecular mechanism of AMPA receptor noncompetitive antagonism.
2005,
Pubmed
,
Xenbase
Bettini,
Identification and characterization of novel NMDA receptor antagonists selective for NR2A- over NR2B-containing receptors.
2010,
Pubmed
Buller,
Glycine modulates ethanol inhibition of heteromeric N-methyl-D-aspartate receptors expressed in Xenopus oocytes.
1995,
Pubmed
,
Xenbase
Cheng,
Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.
1973,
Pubmed
Collingridge,
Synaptic plasticity. The role of NMDA receptors in learning and memory.
,
Pubmed
Costa,
N-methyl-D-aspartate (NMDA) receptor NR2 subunit selectivity of a series of novel piperazine-2,3-dicarboxylate derivatives: preferential blockade of extrasynaptic NMDA receptors in the rat hippocampal CA3-CA1 synapse.
2009,
Pubmed
,
Xenbase
Costa,
A novel family of negative and positive allosteric modulators of NMDA receptors.
2010,
Pubmed
,
Xenbase
Cotman,
Excitatory amino acid neurotransmission: NMDA receptors and Hebb-type synaptic plasticity.
1988,
Pubmed
Furukawa,
Subunit arrangement and function in NMDA receptors.
2005,
Pubmed
Hansen,
Structural and mechanistic determinants of a novel site for noncompetitive inhibition of GluN2D-containing NMDA receptors.
2011,
Pubmed
,
Xenbase
Kalia,
NMDA receptors in clinical neurology: excitatory times ahead.
2008,
Pubmed
Kenakin,
Allosteric modulators: the new generation of receptor antagonist.
2004,
Pubmed
Kutsuwada,
Molecular diversity of the NMDA receptor channel.
1992,
Pubmed
,
Xenbase
Lee,
Exploring the limits of DNA size: naphtho-homologated DNA bases and pairs.
2006,
Pubmed
Lynch,
Pharmacological characterization of heterodimeric NMDA receptors composed of NR 1a and 2B subunits: differences with receptors formed from NR 1a and 2A.
1995,
Pubmed
Madry,
The N-terminal domains of both NR1 and NR2 subunits determine allosteric Zn2+ inhibition and glycine affinity of N-methyl-D-aspartate receptors.
2007,
Pubmed
,
Xenbase
Monyer,
Heteromeric NMDA receptors: molecular and functional distinction of subtypes.
1992,
Pubmed
Moriyoshi,
Molecular cloning and characterization of the rat NMDA receptor.
1991,
Pubmed
,
Xenbase
Mosley,
Quinazolin-4-one derivatives: A novel class of noncompetitive NR2C/D subunit-selective N-methyl-D-aspartate receptor antagonists.
2010,
Pubmed
,
Xenbase
Murphy,
Synthesis and characterization of iodobenzamide analogues: potential D-2 dopamine receptor imaging agents.
1990,
Pubmed
O'Collins,
1,026 experimental treatments in acute stroke.
2006,
Pubmed
Ptak,
Probing the allosteric modulator binding site of GluR2 with thiazide derivatives.
2009,
Pubmed
Rachline,
The micromolar zinc-binding domain on the NMDA receptor subunit NR2B.
2005,
Pubmed
,
Xenbase
Sanacora,
Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders.
2008,
Pubmed
Traynelis,
Glutamate receptor ion channels: structure, regulation, and function.
2010,
Pubmed
Villmann,
On the hypes and falls in neuroprotection: targeting the NMDA receptor.
2007,
Pubmed
Watkins,
Pharmacology of excitatory amino acid transmitters.
1981,
Pubmed
Weaver,
Geometry and charge determine pharmacological effects of steroids on N-methyl-D-aspartate receptor-induced Ca(2+) accumulation and cell death.
2000,
Pubmed
